In contrary, differences in loco-regional control between anemic and non-anemic patients with HNSCC, which were attributed to tumor hypoxia, were substantial [25] but correction of tumor anemia through neither blood transfusion [26] nor recombinant erythropoietin [27] corrected the inferior treatment outcome of anemic patients. The gene discussed is EPO; the disease is head and neck squamous cell carcinoma.